- Home
- NMM vs OCS Comparison
NMM vs OCS Comparison
Compare NMM & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMM | OCS |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | Greece | Switzerland |
| Employees | N/A | 3 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | NMM | OCS |
|---|---|---|
| Price | $65.13 | $24.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | 182.2K | ★ 353.4K |
| Earning Date | 05-06-2026 | 03-03-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.57 | $466.06 |
| Revenue Next Year | $3.66 | $502.05 |
| P/E Ratio | $7.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.37 | $14.00 |
| 52 Week High | $74.21 | $30.68 |
Technical Indicators
Market Signals| Indicator | NMM | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 37.93 |
| Support Level | $58.55 | $19.00 |
| Resistance Level | $74.21 | $29.19 |
| Average True Range (ATR) | 2.73 | 1.21 |
| MACD | -0.13 | -0.25 |
| Stochastic Oscillator | 68.25 | 11.59 |
Price Performance
Historical ComparisonAbout NMM Navios Maritime Partners LP
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.